New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo
Open Access
- 27 January 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (2)
Abstract
In the past decades, the incidence of cryptococcosis has increased dramatically, which poses a new threat to human health. However, only a few drugs are available for the treatment of cryptococcosis. Here, we described a leading compound, NT-a9, an analogue of isavuconazole, that showed strong antifungal activities in vitro and in vivo .Keywords
Funding Information
- Natural Science Foundation of Shanghai Municipality (17ZR1437700)
- National Natural Science Foundation of China (81573473)
- National Natural Science Foundation of China (81830106, 81673280)
This publication has 29 references indexed in Scilit:
- The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattiiAntimicrobial Agents and Chemotherapy, 2016
- Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedsideClinical Microbiology and Infection, 2014
- Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New ApproachesCold Spring Harbor Perspectives in Medicine, 2014
- A neglected epidemic: fungal infections in HIV/AIDSTrends in Microbiology, 2014
- Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated CryptococcosisAntimicrobial Agents and Chemotherapy, 2013
- Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicansJournal of Antimicrobial Chemotherapy, 2013
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapyAIDS, 2006
- What is the current and future status of conventional amphotericin B?International Journal of Antimicrobial Agents, 2006